Maryland Department of Health - Reports on Standing Orders and Opioid Overdose Reversal Drugs

This Maryland bill requires health care providers issuing standing orders for opioid overdose reversal drugs to let patients choose any FDA-approved formulation of the drug. It also mandates that the Maryland Department of Health submit annual reports to state committees by December 1 of 2024, 2025, and 2026 detailing available reversal drugs and explaining why any specific approved drug has not been included in standing orders. These changes aim to increase patient choice and improve transparency regarding access to life-saving medications for individuals at risk of opioid overdose.